TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01062568
Drug: Adrenocorticotropin
Normalized name: Adrenocorticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will have blood drawn at 1900 hr for baseline hormone measurements. At 2200 hr each subject will take a single oral dose of dexamethasone at 2200 hr. At 0700 hr the following day, subjects will have a blood sample drawn for hormone measurements. After this blood sample, adrenocorticotropin (ACTH) will be administered as an iv bolus. At 30 and 60 minutes after Cosyntropin, blood samples will be obtained for repeat hormone measurements.
Study: NCT01062568
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will have blood drawn at 1900 hr for baseline hormone measurements. At 2200 hr each subject will take a single oral dose of dexamethasone at 2200 hr. At 0700 hr the following day, subjects will have a blood sample drawn for hormone measurements. After this blood sample, 0.25 mg adrenocorticotropin (ACTH) will be administered as an iv bolus. At 30 and 60 minutes after Cosyntropin, blood samples will be obtained for repeat hormone measurements.
Study: NCT02998424
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous infusion
Study: NCT00050986
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Starting Dose Level: 100 mg/m\^2 taken by mouth once daily for 7 days, followed by 7 days rest and another 7-day dosing period and 7-day rest period.
Study: NCT00061919
Drug: Carboplatin, etoposide & thalidomide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin IV on day 1 and etoposide IV on day 1 and 2 and, orally Day 3. Oral thalidomide daily beginning on day 1 for up to 24 months.
Study: NCT00061919
Drug: Carboplatin, etoposide & placebo
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin IV on day 1 and etoposide IV on day 1 and 2 and, orally Day 3. Oral placebo daily beginning on day 1 for up to 24 months.
Study: NCT01026389
Drug: Dotarem
Normalized name: Dotarem
DrugBank: Gadoteric acid (DB09132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOTAREM, 0.1 mmoL/kg (0.2 mL/kg), intravenous (I.V.) bolus
Study: NCT01026389
Drug: Gadovist
DrugBank: Gadobutrol (DB06703)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gadovist, 0.1mmol/kg (0.1mL/kg), intravenous (I.V.) bolus
Study: NCT03156504
Drug: Ketamine Hydrochloride
Normalized name: Ketamine Hydrochloride
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive three IV ketamine infusions at 0.5 mg/kg, infused over 100 minutes.
Study: NCT03677895
Drug: Hyaluronic Acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic Acid 2cc into subacromial bursa at weeks 0, 2 and 4
Study: NCT01885078
Drug: Baricitinib
Normalized name: baricitinib
DrugBank: Baricitinib (DB11817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally
Study: NCT02906150
Drug: Thymalfasin (Thymosin alpha 1, Ta1)
Normalized name: thymalfasin
DrugBank: Thymalfasin (DB04900)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomized to Thymosin alpha 1 plus SoC for treatment duration of 12 months. All patients will be followed for approximately 12 months or until the total number of PFS events required will be observed.
Study: NCT02906150
Drug: SoC (chemotherapy and platinum agent)
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomized to SoC for treatment duration of 12 months. All patients will be followed for approximately 12 months or until the total number of PFS events required will be observed.
Study: NCT05353101
Drug: Cyclosporine 0.05% eye drops
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of 0.05% CSA could significantly reduce IL-4, IL-5, IL-17A, and TNF in tears of VKC patients- α、 IFN- γ And eosinophil chemokine levels. Cyclosporine A (CSA) can effectively control ocular inflammation by blocking Th2 lymphocyte proliferation and IL-2 production. It can also inhibit the recruitment of eosinophils by inhibiting the release of histamine by mast cells and reducing the production of IL-5 further to improve its curative effect on VKC
Study: NCT00789269
Drug: rhubarb
Normalized name: Rhubarb
DrugBank: Rhubarb (DB10651)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 days of rhubarb
Study: NCT00722761
Drug: drospirenone and ethinyl estradiol
Normalized name: DROSPIRENONE AND ETHINYL ESTRADIOL KIT
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drosperinone (3mg) and ethinyl estradiol (0.02mg) tablet given once daily for 24 weeks
Study: NCT01396239
Drug: AVI-4658 (Eteplirsen)
Normalized name: AVI-4065
DrugBank: AVI-4065 (DB05620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment group 1 (n=4): 50.0 mg/kg eteplirsen once weekly x 24 weeks via a 60-minute i.v. infusion Treatment group 2 (n=4): 30.0 mg/kg eteplirsen once weekly x 24 weeks via a 60-minute i.v. infusion Treatment group 3 (n=4): matching placebo once weekly x 24 weeks via a 60-minute i.v. infusion; treatment group 3a will match two placebo subjects to 50.0 mg/kg eteplirsen; treatment group 3b will match two placebo subjects to 30.0 mg/kg eteplirsen
Study: NCT02269670
Drug: everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT03827590
Drug: Active Comparator Control 1
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: three times a day for five days
Study: NCT03827590
Drug: Active Comparator Control 2
Normalized name: lactate
DrugBank: L-Phospholactate (DB01733)
Approvals — FDA: no, EMA: no, PMDA: no
Description: three times a day for five days
Study: NCT02269670
Drug: anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT02269670
Drug: letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT02269670
Drug: tamoxifen citrate
Normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT02269670
Drug: fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IM or PO
Study: NCT02269670
Drug: megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol acetate (DB00351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01929655
Drug: Radium-223 dichloride (Xofigo, BAY88-8223)
DrugBank: Radium Ra 223 dichloride (DB08913)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BAY88-8223, 50 kBq/kg will be administered as slow bolus intravenous injection 6 times at intervals of 4 weeks between each administration
Study: NCT02633878
Drug: Chinese Herbal Medicine plus Oral Micronized Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chinese Herbal Medicine (1 pack 2 times a day) + Oral Micronized Progesterone (100 mg three times a day)
Study: NCT02633878
Drug: Chinese Herbal Medicine plus Oral Micronized Progesterone Placebo
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chinese Herbal Medicine (1 pack 2 times a day) + Oral Micronized Progesterone Placebo (100 mg three times a day)
Study: NCT02633878
Drug: Chinese Herbal Medicine Placebo plus Oral Micronized Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chinese Herbal Medicine Placebo (1 pack 2 times a day) + Oral Micronized Progesterone (100 mg three times a day)
Study: NCT02633878
Drug: Chinese Herbal Medicine Placebo plus Oral Micronized Progesterone Placebo
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Chinese Herbal Medicine Placebo (1 pack 2 times a day) + Oral Micronized Progesterone Placebo (100 mg three times a day)
Study: NCT00095368
Drug: Amoxicillin Pulsatile Release Multiparticulate Tablet (drug)
Normalized name: amoxicillin Extended Release Oral Tablet
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03004469
Drug: Finasteride
Normalized name: Finasteride
DrugBank: Finasteride (DB01216)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03004469
Drug: Finasteride Placebo
Normalized name: Finasteride
DrugBank: Finasteride (DB01216)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03565445
Drug: nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenously (IV)
Study: NCT03565445
Drug: pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenously (IV)
Study: NCT02070406
Drug: fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00469404
Drug: Buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00579501
Drug: Trabectedin
Normalized name: Trabectedin
DrugBank: Trabectedin (DB05109)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trabectedin 1.5 mg/m\^2 over a 24-hour iv infusion every 3 weeks for a minimum of 3 and a maximum of 6 cycles of trabectedin.
Study: NCT00579501
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone 20 mg iv will be administered within 30 minutes before start of each trabectedin iv infusion
Study: NCT01549743
Drug: Rebamipide
Normalized name: Rebamipide
DrugBank: Rebamipide (DB11656)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Rebamipide 100mg will be administered orally three times a day for 3 days
Study: NCT01628094
Drug: ribavirin [Copegus]
DrugBank: Ribavirin elaidate (DB17193)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01628094
Drug: ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00620971
Drug: Vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vinorelbine (oral) 60 mg/m2, on days 1 and 8 every 3 weeks for 3 cycles
Study: NCT00620971
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (IV) 80 mg/m2 on day 1 every 3 weeks for 3 cycles
Study: NCT00620971
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 3 cycles
Study: NCT00620971
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel (IV) 75 mg/m2 on day 1 every 3 weeks for 6 cycles
Study: NCT00620971
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine(IV) 1,100 mg/m2 on day 1 and d8 every 3 weeks for 6 cycles
Study: NCT00620971
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles
Study: NCT00620971
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (IV) 80 mg/m2 on day 1 every 3 weeks for 6 cycles
Study: NCT04130828
Drug: Ferrous Fumarate
Normalized name: Ferrous Fumarate
DrugBank: Ferrous tartrate (DB13639)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous fumarate 200 mg PO PC
Study: NCT00195767
Drug: divalproex sodium
Normalized name: Divalproex Sodium
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02503774
Drug: Oleclumab
Normalized name: Oleclumab
DrugBank: Oleclumab (DB15088)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive IV infusion of oleclumab as stated in arms' description.
Study: NCT02503774
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive IV infusion of durvalumab as stated in arms' description.
Study: NCT02482441
Drug: OMP-131R10
Normalized name: OMP-54F28
DrugBank: Ipafricept (DB15045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: There are 5 planned dose cohorts of OMP-131R10. Dose escalation will follow a traditional 3+3 framework. Treatment will be continued until progressive disease or unacceptable toxicity.
Study: NCT01222572
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01222572
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04353336
Drug: Chloroquine or Hydroxychloroquine
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine or Hydroxychloroquine
Study: NCT00432094
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Days -6, -5, -4: 500mg/m2\^/day intravenously (IV) over 60 minutes
Study: NCT00432094
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600mg/m\^2/day intravenously (IV) over 60 minutes on Days -6 through -3.
Study: NCT06021717
Drug: Ketamine-Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PCA ketamine (Ketamine HCl, Pfizer Inc., US) 0.5 mg plus morphine 0.5 mg ml-1 (ratio 1:1)
Study: NCT06021717
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PCA morphine (Pfizer Inc., US) 1 mg ml-1
Study: NCT02465593
Drug: 5-fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 225 mg/m2 a day, 5 days/week for 5 weeks during radiotherapy period
Study: NCT01389973
Drug: ustekinumab 90 mg
Normalized name: ustekinumab 90 MG/ML
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous injections of ustekinumb 90 mg at Weeks 0 and 4 and every 8 weeks until the dose for the Long-Term Extension has been selected then every 8 weeks through Week 196 with the selected dose.
Study: NCT01389973
Drug: ustekinumab 45 mg
Normalized name: ustekinumab 45 MG in 0.5 mL Injection
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous injections of ustekinumb 45 mg at Weeks 0 and 4 and every 8 weeks until the dose for the Long-Term Extension has been selected then every 8 weeks through Week 196 with the selected dose.
Study: NCT01389973
Drug: ustekinumab 180 mg
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous injections of ustekinumb 180 mg at Weeks 0 and 4 and every 8 weeks until the dose for the Long-Term Extension has been selected then every 8 weeks through Week 196 with the selected dose.
Study: NCT03009526
Drug: Sulfadoxine-pyrimethamine
Normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg sulfadoxine and 25 mg pyrimethamine
Study: NCT03009526
Drug: dihydroartemisinin-piperaquine
Normalized name: .alpha.-dihydroartemisinin
DrugBank: Artemisinin (DB13132)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg dihydroartemisinin and 320 mg piperaquine
Study: NCT00432094
Drug: ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2500 mg/m\^2/day continuous infusion intravenously on Days -6, -5 and -4.
Study: NCT00432094
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 225 mg/m\^2 intravenous over 3 hours on Day -7.
Study: NCT00432094
Drug: thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 150mg/m\^2/day intravenously IV over 30 minutes; Days -6, -5 and -4
Study: NCT00432094
Drug: Mesna
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2500 mg/m\^2/day continuous infusion intravenously on Days -6, -5 and -4.
Study: NCT01763021
Drug: PCI-32765
Normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCI-32765 will be administered as a single oral dose of PCI-32765 560 mg on Day 1 and Day 11
Study: NCT01763021
Drug: Rifampin
Normalized name: Rifampin
DrugBank: Rifampin (DB01045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin 600 mg (2 X 300 mg) daily dose will be administered orally from Day 4 to Day 13 and on Day 11 along with PCI-32765.
Study: NCT00375687
Drug: Triptorelin
Normalized name: triptorelin
DrugBank: Triptorelin (DB06825)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00433784
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02723838
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 cycles (each cycle = 21 days). Cohort 1: 1000mg/m2 intravenously on Day 2 and Day 9 of Cycle 2 and Cycle 3. Cohort 2: 1000mg/m2 intravenously on Day 1 and Day 8 of each cycle.
Study: NCT02723838
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 cycles (each cycle = 21 days). Cohort 1: 70 mg/m2 intravenously on Day 2 of Cycle 2 and Cycle 3. Cohort 2: 70 mg/m2 intravenously on Day 1 of each cycle.
Study: NCT01732367
Drug: Lamivudine plus adefovir
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine 100mg QD for 96 weeks + Adefovir 10mg QD for 96 weeks
Study: NCT04151355
Drug: Atorvastatin 20mg
Normalized name: AMLODIPINE 5MG/ATORVASTATIN 20MG TAB
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: atorvastatin (20 mg once daily)
Study: NCT00178048
Drug: paroxetine
Normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04561921
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patients will be given an IANB injection by adding 0.18 mL of 10% magnesium sulphate to 1.8 ml of 2% mepivacaine HCL with Levonordefrin HCl 1:20000/ 1.8 ml , after withdrawal of 0.18ml from the local anesthetic carpule by using a 100 IU insulin syringe
Study: NCT04561921
Drug: Mepivacaine-Levonordefrin Hydrochloride
Normalized name: Mepivacaine-Levonordefrin Hydrochloride
DrugBank: Mepivacaine (DB00961)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients will be given an IANB injection by adding 0.18 mL of sterile distilled water to 1.8 ml of 2% mepivacaine HCL with Levonordefrin HCl 1:20000/ 1.8 ml , after withdrawal of 0.18ml from the local anesthetic carpule by using a 100 IU insulin syringe
Study: NCT00974051
Drug: Terbutaline
Normalized name: Terbutaline
DrugBank: Terbutaline (DB00871)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral (2.5mg) one time administration at 9:00pm
Study: NCT01732367
Drug: Tenofovir
Normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tenofovir 300mg QD for 96 weeks
Study: NCT03822871
Drug: 68Ga-PSMA-11
Normalized name: 68Ga-Psma-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be screened with CTT1057 or 68Ga-PSMA-11 PSMA PET to demonstrate presence of at least 3 PSMA avid lesions that can be targeted by the study drug, CTT1403. 5-7 weeks after administration of study drug, patients will be evaluated a second time with PSMA PET imaging using with either CTT1057 or 68Ga-PSMA-11 to assess potential efficacy of CTT1403.
Study: NCT02418533
Drug: menotropin
Normalized name: Menotropin
DrugBank: Menotropins (DB00032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menopur is used for controlled ovarian stimulation (COH)
Study: NCT00803543
Drug: Valacyclovir
Normalized name: Valacyclovir
DrugBank: Valaciclovir (DB00577)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 500 mg tablets. Dosage two tablets (1000 mg)once daily for 24 weeks
Study: NCT03670069
Drug: Itacitinib
Normalized name: itacitinib
DrugBank: Itacitinib (DB12154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT04514159
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Abemaciclib (VERZENIO®) is an approved drug.
Study: NCT01408667
Drug: TRC150094
Normalized name: TRC150094
DrugBank: TRC150094 (DB16046)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg Tablets once a day
Study: NCT04154787
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Comparison of rituximab dose
Study: NCT00163072
Drug: transdermal Megace
Normalized name: megestrol acetate Oral Tablet [Megace]
DrugBank: Megestrol acetate (DB00351)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral vs transdermal levels
Study: NCT00511342
Drug: LNG-EE
Normalized name: norgestimate
DrugBank: Norgestimate (DB00957)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levonorgestrel and Ethinyl Estradiol Tablets, 0.150 mg Levonorgestrel and 0.030 mg Ethinyl Estradiol taken once daily from Day 1 of menstrual period up to and including Day 28 for 26 consecutive 28-day menstrual cycles (2 years).
Study: NCT00576251
Drug: TOBRADEX
Normalized name: Tobradex
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: TOBRADEX 1 drop in both eyes 4 times daily for at least 3 days
Study: NCT02010437
Drug: Sodium Tetradecyl Sulphate (STS)
DrugBank: Sodium tetradecyl sulfate (DB00464)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01437449
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg/m² by intravenous (IV) administration
Study: NCT01437449
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg/m² by intravenous (IV) administration
Study: NCT01437449
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 400 mg/m² by intravenous (IV) administration, thereafter 250 IV
Study: NCT01437449
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Area under the free carboplatin plasma concentration versus time curve (AUC)=2 by intravenous (IV) administration